Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association.Stroke. 2017; 48: e284-e303
- Preventing dementia by preventing stroke: the Berlin Manifesto.Alzheimer’s Dement. 2019; 15: 961-984
- Vascular dysfunction—the disregarded partner of Alzheimer’s disease.Alzheimer’s Demen. 2019; 15: 158-167
- NIA-AA research framework: toward a biological definition of Alzheimer’s disease.Alzheimer’s Demen. 2018; 14: 535-562
- (Available at:) (Accessed online, March 2022)
- Vascular cognitive impairment (Chapter 6).in: Lazar R.M. Pavol M.A. Browndyke J.N. Neurovascular neuropsychology. 2nd edition. Springer, Cham, Switzerland2020: 121-138
- Subcortical arteriosclerotic encephalopathy (Binswanger): computerized tomography.Neurology. 1979; 29: 1102-1106
- Matrix metalloproteinase-mediated neuroinflammation in vascular cognitive impairment of the binswanger type.Cell Mol Neurobiol. 2016; 36: 195-202
- Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - a consensus report.BMC Neurol. 2017; 17 (Article number: 102)
- Diagnostic and prognostic blood biomarkers in vascular dementia: from the viewpoint of ischemic stroke.Neurochem Int. 2021; 146: 105015
- Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application.Int J Mol Sci. 2019; 20: 2812
- Vascular contributions to cognitive impairment and dementia.Stroke. 2011; 42: 2672-2713
- Association of cardiovascular risk trajectory with cognitive decline and incident dementia.Neurology. 2022; 98: e2013-e2022
- MARKVCID website.(Available at:) (Accessed July 12, 2022)
- Disclosing Alzheimer disease biomarker results to research participants.JAMA Neurol. 2022; 79: 645-646
- Alzheimer’s disease.Lancet. 2021; 397: 1577-1590
- Tau biomarkers in Alzheimer’s disease: toward implementation in clinical practice and trials.Lancet Neurol. 2022; 21: 726-734
- Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia.JAMA. 2019; 321: 2316-2325
- Amyloid pathology but not APOE e4status is permissive for tau-related hippocampal dysfunction.Brain. 2022; 145: 1473-1485
- Association of midlife plasma amyloid-beta levels with cognitive impairment in late life.Neurology. 2021; 97: e1123-e1131
- Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer’s disease.JAMA Neurol. 2021; 78: 1375-1382
- Alzheimer’s Res Ther. 2022; 14: 20https://doi.org/10.1186/s13195-022-00967-z
- Plasma p-tau231, p-tau 181, PET biomarkers, and cognitive change in older adults.Ann Neurol. 2022; 91: 548-560
- Associations of fully automated CSF and novel plasma biomarkers with Alzheimer’s disease neuropathology at autopsy.Neurology. 2021; 97: e1229-e1242
- Commentary on Oeckl et al., “Serum Beta-Synuclein is Higher in Down’s Syndrome and Precedes Rise of pTau181”.Ann Neurol. 2022; 92: 3-5
- Association of serum neurofilament light chain concentration and MRI findings in older adults. The Cardiovascular Health Study.Neurology. 2022; 98: e903-e911
- Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia.Nat Aging. 2021; 1: 26-28
- Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive impairment.Neurology. 2022; 98: e1315-e1326
- Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease.Brain. 2022; (Online ahead of print): awac128https://doi.org/10.1093/brain/awac128
- Alzheimer's disease: scientific breakthroughs and translational challenges.Mayo Clin Proc. 2017; 92: 978-994
- DNA methylation and protein markers of chronic inflammation and their associations with brain and cognitive aging.Neurology. 2021; 97: e2340-e2352
- New insights into the genetic etiology of Alzheimer’s disease and related dementias.Nat Genet. 2022; 54: 412-436
- A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk.Nature. 2022; 603: 885-892
- Automated detection of mild cognitive impairment and dementia from voice recordings: a natural language processing approach.Alzheimer’s Dement. 2022; : 1-10https://doi.org/10.1002/alz.12721
- Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group.Lancet Neurol. 2021; 20: 484-496
Article info
Publication history
Published online: October 18, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
